Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 85-92

  Fumoleau, P ^a   Roche H ^b   Kerbrat, P ^c   Bonneterre, J ^d   Romestaing, P ^e   Fargeot, P ^a   Namer, M ^f   Monnier, A ^g   Montcuquet, P ^h   Goudier, M J ⁱ   Luporsi, E ^j  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e Centre Hospitalier Jules Courmont   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g Centre Hospitalier André Boulloche   (France)

^h Clinique Saint Vincent   (France)

ⁱ Centre Hospitalier de Bretagne Sud   (France)

^j CENTRE ALEXIS VAUTRIN   (France)

more..

Author keywords

Adjuvant chemotherapy; Breast cancer; Cardiotoxicity; Epirubicin

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; NAVELBINE; TAMOXIFEN;

ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; BRADYCARDIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG DOSE REGIMEN; DRUG FATALITY; EXTRASYSTOLE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MASTECTOMY; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC HEART MURMUR; TACHYCARDIA; THROMBOEMBOLISM;

EID: 29844458403     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj034     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
2. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25 (Suppl 10): 72-85.
3. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 9: 710-717.
4. Praga C, Beretta G, Vigo PL et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 62: 931-934.
5. Bonadonna G, Gianni L, Santoro A et al. Drugs ten years later: epirubicin. Ann Oncol 1993; 4: 359-369.
6. Mouridsen HT. New cytotoxic drugs in treatment of breast cancer. Acta Oncol 1990; 29: 343-347.
7. Ewer MS, Benjamin RS. Cardiac complications. In Holland J, Frei E (eds): Cancer Medicine, 5th edition. Philadelphia, PA: Decker BC 2000; 2324-2339.
8. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743.
9. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.
10. Valagussa P, Zambetti M, Biasi S et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994; 5: 209-216.
11. Corn BW, Trock BJ, Goodman RL. Irradiation-related ischemic heart disease. J Clin Oncol 1990; 8: 741-750.
12. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ABR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992; 52: 194-201.
13. Torti FM, Bristow MM, Lum BL et al. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722-3727.
14. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679-688.
15. Italian Multicentre Breast Study with Epirubicin. Phase III randomised study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian Multicentre Trial. J Clin Oncol 1988; 6: 976-982.
16. Lopez M, Papaldo O, Di Lauro L et al, 5-Fluorouracil, adriamycin, cyclophesphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophasphamide (FEC) in metastatic breast cancer. Oncology 1989; 46; 1-5.
17. Shapiro CL, Hardenbergh P, Gelman R et al, Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16: 3493-3501.
18. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with dexorubicin. A retrospective analysis of three trials, Cancer 2003; 97: 2869-2879.
19. Fumoleau P, Roche H, Asselain B et al. Evaluation of early cardiotoxicity in breast cancer patients treated with epirubicin-based adjuvant chemotherapy: Results from the PACs 01 study. Proc Am Soc Clin Oncol 2001; 20: Abstr 107.
20. Bonneterre J, Roche H, Kerbrat P et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group, J Clin Oncol 2004; 22: 3070-3079.
21. Fargeot P, Bonneterre J, Roche H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial, J Clin Oncol 2004; 22: 4622-4630,
22. Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma treponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-715.
23. Okumura H, luchi K, Yoshida T et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity, Acta Haematol 2000; 104: 158-163.
24. Hensley ML, Schuchter LM, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-3355.
25. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999; 3: 145-159.
26. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor-efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
27. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med 2001; 344: 783-792.
28. Luck HJ, Thomssen C, Du Bois A et al. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin. Oncology 1998; 12: 36-39.
29. Langer B, Muscholl M, Pauschinger M et al. A prospective study of NT-pro brain natriuretic peptide and troponin T in the HERCULES study (epirubicin + cyclophosphamide with or without herceptin) in patients with metastatic breast cancer. San Antonio Breast Cancer Symposium 2003: Abstr 223.